Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exenatide implant is a long-acting drug-device combination that delivers the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide via a miniature subdermal medical implant. It is designed to provide sustained release of exenatide for up to six months, aiming to improve glycemic control in adults with type 2 diabetes mellitus and support weight loss in obesity. The mechanism of action involves GLP-1 receptor agonism, which stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces food intake. The technology seeks to address medication non-adherence and tolerability issues associated with oral or injectable formulations by offering consistent therapeutic delivery over an extended period[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on exenatide implant.